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Figure 1: . Serologic and stool-based 
infectious assessment for OpenBiome stool 
donors.
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BACKGROUND
The annual healthcare expenditure in the United States 
for the management of Clostridium difficile infection 
(CDI) is estimated to be 3.2 billion dollars.  These 
costs are rising with increased rate of CDI since 2000. 
Recurrent CDI (RCDI) occurs in 10-20% of patients 
after initial treatment. In this population, the rate of 
additional recurrences increases to 40-65%. Guidelines 
recommend the use of fecal microbiota transplant (FMT) 
after a third relapse of CDI. We evaluated the efficacy 
as well as the healthcare savings provided by FMT in 
patients with RCDI.
DISCUSSION
FMT is an effective modality for treating patients with RCDI with mean primary cure rates of 91%. Our primary 
cure rate of 83.7% represents an improvement over usual antibiotic therapy. Conservative estimates are each 
patient treated with successful FMT saves $17,000 in healthcare costs. Using this, the 38 successful FMT 
procedures performed over a 20-month period led to $646,000 in savings. The cost of the 60 samples used or 
discarded in the treatment of these patients was $20,100. One unique finding was the association of inadequate 
bowel preparation and successful treatment. It is possible that patients who are unable to adequately clear their 
colon before a procedure may be more likely to retain the transplanted fecal material, giving it an extended 
period to take effect.
We performed a retrospective single-center study at a 
large tertiary care teaching hospital.  A chart review of 
patients who had undergone FMT between October 1, 
2015 and May 30, 2017 was done. Patients were eligible 
for FMT treatment if they had at least three recurrent 
episodes of CDI with at least one trial of pulsed-dose oral 
vancomycin. In eligible patients 250 mL of donor fecal 
material was endoscopically delivered in the right colon. 
Phone call follow up was performed one week after FMT 
to assess for symptom resolution.
METHODS
 Table 1. Patient Characteristics for Primary Outcome




Age 62.6 + 15.1 64.0 + 17.6 0.8296
Male Gender 12 (33.3%) 2 (28.6%) 1.0000
Prior Fidaxomicin 6 (16.7%) 0 (0.0%) 0.5671
IBD History 3 (8.3%) 0 (0.0%) 1.0000
Immunosuppression 5 (13.9%) 1 (14.3%) 1.0000
Poor Bowel Prep 9 (25.0%) 0 (0.0%) 0.3135
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RESULTS
Patient characteristics are noted in Table 1.  A total of 50 
fecal transplants were performed on 45 patients. Two 
patients were lost to follow up. In a per-protocol analysis, 
36 patients (83.7%) had resolution of infection after their 
first transplant. Five patients failed treatment and did 
not undergo repeat FMT. Two patients were successfully 
treated with a second FMT, increasing the success rate 
to 88.4%. Three patients were retreated after delayed 
recurrence more than 180 days after initial FMT. Two 
of those improved with a second FMT while one failed 
retreatment. No adverse events were noted.
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